Literature DB >> 31446435

The Roles of Circular RNAs in Osteosarcoma.

Yong Zhang1, Jiale Li1, Yinsheng Wang1, Juehua Jing1, Jun Li1.   

Abstract

Osteosarcoma is a malignant tumor that occurs most commonly in the metaphysis of the long bones in the limbs in children and adolescents. Even with surgery and neoadjuvant chemotherapy, the therapeutic effect has reached a peak with 60-70% survival rates. Therefore, new biological targets or molecular mechanisms that enhance the efficacy of osteosarcoma treatments are needed. Circular RNAs (circRNAs) are useful biomarkers that have recently been recognized clinically and in medical research and have been of interest due to the use of next-generation sequencing and bioinformatics analysis. CircRNAs are involved in many diseases, including cancer. Therefore, this review aims to summarize the roles of circRNA in the diagnosis, progression, and prognosis of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31446435      PMCID: PMC6724563          DOI: 10.12659/MSM.915559

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Osteosarcoma is a malignant tumor that is most common in the metaphyses of limbs in both children and teenagers [1], and the distal femur, humerus, and proximal tibia are hot spots [2]. Also, in adolescents, osteosarcoma has a second peak in the population over 50 years old. Osteosarcoma consists of malignant osteoblasts that produce immature bone or osteoid tissue. The treatment of osteosarcoma consists of surgery in early stages and adjuvant chemotherapy (began in the 1970s) to neoadjuvant chemotherapy, which is the present standard therapy [3]. Also, the cure rates of patients with non-metastatic osteosarcoma were less than 20% [4], which increased to almost 50% [5] and are currently 70%. However, patients with metastasis and chemotherapy drug resistance suffer from dismal survival rates [6], and lung metastasis is the most frequent complication. Therefore, to enhance the efficacy of osteosarcoma treatment, new biological targets or new molecular mechanisms are needed. CircRNA has recently been recognized as a useful biomarker by clinicians and researchers. CircRNA acts as a microRNA (miRNA) sponge and is a novel endogenous RNA that competes for microRNAs and long noncoding RNAs [7]. CircRNA was first identified in the 1970s and is characterized by covalently closed loop structures and the lack of 3′ and 5′ polyadenylated tails [8,9]. Therefore, circRNA is more conservative and stable than the corresponding linear RNA [10]. CircRNAs come from different sources and produce different circRNAs [11]. For example, circRNAs can originate from coding precursor mRNA (pre-mRNA), noncoding mRNA (ncRNA), mature mRNA, intron lariats, and intergenic genes. The types of circRNAs include exonic circular RNA (ecircRNA), exon-intron circRNA (ElciRNA), intergenic circRNA, and antisense circRNA. Initially, circRNA did not receive attention from researchers and was considered to be the subsidiary products of splicing errors. With improved next-generation sequencing and bioinformatics analysis, increased research on circRNA has been conducted. Many circRNAs are involved in the progression of multiple diseases, especially tumorigenesis [12], and their characteristics of conservation, stability, specificity, richness, and easy detection were recognized [13]. Hence, circRNA is considered a new and useful tumor biomarker [14,15]. In this review, we summarize the roles of circRNA in the progression, prognosis, and diagnosis of osteosarcoma.

CircRNAs in the Progression of Osteosarcoma

To investigate the functions of circRNAs in the progression of osteosarcoma, researchers usually conduct a circRNA microarray analysis of osteosarcoma tissues and cell lines or screen microarray datasets to identify a novel circRNA that may be involved in the proliferation of osteosarcoma cells. Considering that circRNAs function as a miRNA sponge, it is essential to filter the target miRNAs of circRNAs. Bioinformatics tools such as miRBase predict the potential target miRNAs and are verified by luciferase reporter assays. The relationship between circRNA and selected target miRNA has been further confirmed by loss-of-function and gain-of-function analysis, following which the oncogenic function of the circRNA has been confirmed by rescue assays to support the experimental findings. The oncogenic function of overexpressed circRNA involves promotion of cell proliferation, colony formation, and invasion and reduction in the apoptotic cell rate. For example, CircRNA GLI2 positively affects cell proliferation, invasion, and migration and negatively affects apoptosis. The oncogenic function of downregulated circRNAs such as circ_0002052 contrasts that of overexpressed circRNAs. Some investigators have generated xenografts of osteosarcoma cells in nude mice and found that overexpression of certain circRNAs, such as circ_0001721 and circ_0000502, promoted tumor volume and weight increase. Also, circ_0009910, circRNA NASP, and circ_0001564 were confirmed to affect G0/G1 arrest negatively. Furthermore, circRNA can act through some tumor-related pathways and plays a carcinogenic role. For example, a rescue assay showed that the oncogenic function of circ_0009910 partly depends on the JAK1/STAT3 pathway, which is involved in apoptosis and proliferation [16]. CircRNAs that affect the progression of osteosarcoma are described in Table 1.
Table 1

Characterization of circRNAs that affect the progression of osteosarcoma.

CircRNADeregulationGenes/proteins affectedRoles
Circ_0008717 [17]OverexpressionmiR-203/Bmi-1Proliferation (+), invasion (+), migration (+), apoptosis (−)
Circ_0009910 [18]OverexpressionmiR-449a/IL6R/JAK1-STAT3Proliferation (+), apoptosis (−), G0/G1 arrest (−)
CircRNA_GLI2 [19]OverexpressionmiR-125b-5pProliferation (+), invasive (+), migration (+), apoptosis (−)
CircRNA_NASP [20]OverexpressionmiR-1253/FOXF1Proliferation (+), G0/G1 arrest (−)
Circ_0001721 [21]OverexpressionmiR-569 and miR-599Proliferation (+), tumor volume (+), tumor weight (+), apoptosis (−)
Circ_0007534 [22]OverexpressionAKT/GSK-3β pathway, Bcl-2/caspase-3 pathwayProliferation (+), invasion (+), tumor weight (+), apoptosis (−)
Circ_0002052 [23]Low-ExpressionmiR-1205/APC2/Wnt/β-cateninApoptosis (+), tumor growth (−), proliferation (−)
circ_0000502 [24]OverexpressionmiR-1238Migration (+), proliferation (+), invasion (+), tumor volume (+), tumor weight (+), apoptosis (−)
Circ_001569 [25]Overexpression/Proliferation (+), clone formation (+)
circRNA_CDR1as [26]OverexpressionmiR-7Cell vitality (+), migration (+), tumor growth (+), G1/S arrest (−)
circ-0016347 [27]OverexpressionmiR-214/caspase-1Oncogenic ability (+)
Circ_0001564 [28]OverexpressionmiR-29c-3pProliferation (+), G0/G1 arrest (−), apoptosis (−)
Circ-NT5C2 [29]OverexpressionmiR-448Proliferation (+), invasion (+), tumor growth (+)
CircFAT1 [30]OverexpressionmiR-375/YAP1Proliferation (+), migration (+), apoptosis (−)
CircRNA UBAP2 [31]OverexpressionmiR-143/Bcl-2Oncogenic ability (+)

CircRNAs in the Prognosis of Osteosarcoma

To determine the relationship between circRNA expression and prognosis in osteosarcoma, correlation analysis has shown that the expression of circRNA in osteosarcoma was related to certain prognostic factors, such as tumor size, Enneking stage, and the occurrence of distant metastasis. For example, Fisher’s exact test showed that the level of circ_0007534 was related to tumor size and degree of differentiation or tumor grade, but not to the World Health Organization (WHO) stage and in advanced osteosarcoma associated with pulmonary metastasis. For circ_0000502, all tumor sizes, WHO grades and stage, and pulmonary metastasis rates in the overexpression group were higher than those in the low-expression group. CircRNA CDR1 and circ_001569 were upregulated in OS, and both were associated with tumor size, Enneking stage (or TNM stage), and pulmonary metastasis but not patient age, or gender. Neoadjuvant chemotherapy is currently the standard therapy for osteosarcoma, and chemoresistance can influence the prognosis of osteosarcoma. Zhang et al. found that suppression of circ_001569 activity in osteosarcoma cell lines led to decreased IC50 values for doxorubicin, methotrexate, or cisplatin, and Wnt/β-catenin pathway agonist rescued the decreased IC50 values. Additionally, the Wnt/β-catenin pathway is reportedly involved in osteosarcoma chemoresistance [32]. Therefore, circ_001569 may promote cisplatin resistance through the Wnt/β-catenin pathway. Circ_0081001 was selected from chemoresistant and chemosensitive osteosarcoma cell lines, and further experiments demonstrated that circ_0081001 levels were higher in advanced Enneking stage patients, chemoresistant patients, and lung metastasis patients. Thus, circ_0081001 may be a potential biomarker for prognosis of osteosarcoma. Meanwhile, the relationship between the expression of circRNAs and survival rates, including 5-year survival rates, overall survival time, and disease-free survival time, of osteosarcoma patients was detected by Kaplan-Meier analysis. Circ_0001721 and circ_0000502 were negatively correlated with 5-year survival rates; circRNA UBAP2 and circRNA PVT1 were negatively correlated with overall survival time, whereas circRNA HIPK3 was positively correlated with overall survival time. Moreover, circRNA NT5C2 was negatively correlated with overall survival and disease-free survival. The circRNAs that affect the prognosis of osteosarcoma are described in Table 2.
Table 2

Characterization of circRNAs that affect the prognosis of osteosarcoma.

CircRNADeregulationGenes/proteins affectedRoles
Circ_0008717 [17]OverexpressionmiR-203/Bmi-1Clinical stage (+), distant metastasis (+), overall survival (−), disease-free survival (−)
Circ_0001721 [21]OverexpressionmiR-569, miR-599WHO grade (+), tumor size (+), 5-year overall survival (−)
Circ_0007534 [22]OverexpressionAKT/GSK-3β pathway, Bcl-2/caspase-3 pathwayTumor size (+), differentiation grade (+), overall survival rates (−)
Circ_0002052 [23]OverexpressionmiR-1205/APC2/Wnt/ β-cateninClinical stage (+), distant metastasis (+), overall survival (−), disease-free survival (−)
Circ_0000502 [24]OverexpressionmiR-1238WHO grade (+), tumor size (+), pulmonary metastasis (+), 5-year prognosis (−)
Circ_001569 [25]Overexpression/Distant metastasis (+), TNM stage (+), chemotherapeuti-c resistance (+)
circRNA_ CDR1as [26]OverexpressionmiR-7Tumor size (+), enneking stage (+), pulmonary metastasis (+)
CircRNA_UBAP2 [31]OverexpressionmiR-143/Bcl-2Tumor stages (+), overall survival (−)
circ_HIPK3 [33]Low-expression/Overall survival (−), enneking stage (+), lung metastasis (+)
circ-NT5C2 [34]Overexpression/Clinical stage (+), distant metastasis (+), overall survival (−), disease-free survival (−)
CircPVT1 [35]OverexpressionGene ABCB1Lung metastasis (+), chemoresistant (+), enneking stage (+), overall survival (−)
Circ_0081001 [36]Overexpression/Enneking stage (+), lung metastasis (+), chemoresistant (+), overall survival (−)

CircRNAs in the Diagnosis of Osteosarcoma

Circ_0008717 was shown to be upregulated in patients with osteosarcoma. The value of the area under the curve (AUC) was 0.782, and the diagnostic specificity and sensitivity were 0.73 and 0.80, respectively. CircRNA-CDR1as was upregulated in osteosarcoma tissues and cell lines, and receiver operating characteristic (ROC) curve analysis indicated that circRNA-CDR1as was a novel diagnostic marker of osteosarcoma as the value of the AUC reached 0.857. CircRNA-NT5C2 was overexpressed in osteosarcoma tissues, and the AUC value was 0.753. Therefore, circRNA-NT5C2 may be an excellent diagnostic label to distinguish osteosarcoma patients from healthy individuals. CircRNA-HIPK3was downregulated in osteosarcoma tissues and plasma. To explore the diagnostic value of circRNA-HIPK3, a ROC curve was drawn, and the cutoff value was 29.3. The sensitivity value was 56%, and the specificity was 84%. CircRNA-PVT1 was not only upregulated in osteosarcoma tissues but was also overexpressed in sera, making circRNA-PVT1 easy to detect as a diagnostic marker. Also, the area under the curve (AUC) value of circRNA-PVT1 (0.871) was equivalent to lactate dehydrogenase (LDH) (0.852), which was greater than alkaline phosphatase (ALP) (0.673), both of which are clinical diagnostic markers in osteosarcoma. Zhu et al. also investigated the diagnostic value of circ_0081001, and the AUC value of circ_0081001 was 0.898, which was similar to circPVT1 (0.871). Table 3 lists the circRNAs that could be potential diagnostic biomarkers of osteosarcoma.
Table 3

Characterization of circRNAs that could be diagnostic biomarkers of osteosarcoma.

CircRNADeregulationGenes/proteins affectedDiagnostic value
Circ_0008717 [17]OverexpressionmiR-203/Bmi-1AUC value: 0.782, sensitivity value: 0.8, specificity value: 0.73
circRNA_ CDR1as [26]OverexpressionmiR-7AUC value: 0.857
Circ-NT5C2 [29]OverexpressionmiR-448AUC value: 0.753
circ_HIPK3 [33]Overexpression/Cutoff value: 29.3, sensitivity value: 0.56, specificity value: 0.84
CircPVT1 [35]OverexpressionGene ABCB1AUC value: 0.871
Circ_0081001 [36]Overexpression/AUC value: 0.898
CircRNA is more abundant and stable than its liner RNA counterparts. With the improvement of next-generation sequencing and bioinformatics analysis, the function of circRNA is increasingly well known, especially in cancers. Recently, circRNA has been identified as a potential novel biomarker and an underlying therapeutic target in osteosarcoma.

Conclusions

In this review, we summarized the function of circRNAs in the progression, prognosis, and diagnosis of osteosarcoma and their predicted downstream miRNAs or potential signaling pathways. However, many circRNAs remain undetected, and their functions in osteosarcoma have not been verified. Also, further studies are needed to investigate the differentially upregulated circRNAs and downregulated circRNAs in osteosarcoma tissues and cell lines. Isolated circRNAs have been reviewed as biomarkers in osteosarcoma, and interactions between or among circRNAs have not been reviewed. Although bioinformatics analysis has identified networks among circRNAs, few studies have confirmed these findings in vivo and in vitro and further studies are needed.
  36 in total

1.  Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study.

Authors:  Rajaram Nagarajan; Anmmd Kamruzzaman; Kirsten K Ness; Victoria G Marchese; Charles Sklar; Ann Mertens; Yutaka Yasui; Leslie L Robison; Neyssa Marina
Journal:  Cancer       Date:  2010-10-04       Impact factor: 6.860

2.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Circular RNA circNASP modulates the malignant behaviors in osteosarcoma via miR-1253/FOXF1 pathway.

Authors:  Lipeng Huang; Mangmang Chen; Jun Pan; Weiyang Yu
Journal:  Biochem Biophys Res Commun       Date:  2018-04-21       Impact factor: 3.575

4.  Upregulation of circular RNA circ_0000502 predicts unfavorable prognosis in osteosarcoma and facilitates cell progression via sponging miR-1238.

Authors:  Hongfei Qi; Yue Sun; Yuehong Jiang; Xiaolin Li
Journal:  J Cell Biochem       Date:  2018-12-07       Impact factor: 4.429

Review 5.  Advances of circular RNAs in carcinoma.

Authors:  Xiao-Yue Xu; Lei-Lei Zhou; Chen Yu; Bo Shen; Ji-Feng Feng; Shao-Rong Yu
Journal:  Biomed Pharmacother       Date:  2018-08-02       Impact factor: 6.529

6.  TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin.

Authors:  Jianhuang Wu; Qiande Liao; Hongbo He; Da Zhong; Ke Yin
Journal:  Mol Carcinog       Date:  2012-12-31       Impact factor: 4.784

7.  Circular RNA circ-NT5C2 acts as a potential novel biomarker for prognosis of osteosarcoma.

Authors:  W-B Nie; L-M Zhao; R Guo; M-X Wang; F-G Ye
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-10       Impact factor: 3.507

8.  High-throughput data integration of RNA-miRNA-circRNA reveals novel insights into mechanisms of benzo[a]pyrene-induced carcinogenicity.

Authors:  Florian Caiment; Stan Gaj; Sandra Claessen; Jos Kleinjans
Journal:  Nucleic Acids Res       Date:  2015-02-17       Impact factor: 16.971

9.  Circular RNA hsa-circ-0016347 promotes proliferation, invasion and metastasis of osteosarcoma cells.

Authors:  Hao Jin; Xin Jin; Hong Zhang; Wenbo Wang
Journal:  Oncotarget       Date:  2017-04-11

10.  TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p.

Authors:  Jiaqing Cao; Xinyou Han; Xin Qi; Xiangyun Jin; Xiaolin Li
Journal:  Int J Oncol       Date:  2017-08-30       Impact factor: 5.650

View more
  14 in total

1.  Downregulation of hsa_circ_0000885 suppressed osteosarcoma metastasis and progression via regulating E2F3 expression and sponging miR-16-5p.

Authors:  Yanfang Li; Zhiqing Wu; Jianlin Shen
Journal:  Regen Ther       Date:  2022-06-22       Impact factor: 3.651

Review 2.  The Landscape of Regulatory Noncoding RNAs in Ewing's Sarcoma.

Authors:  Connor Barrett; Anuj Budhiraja; Vijay Parashar; Mona Batish
Journal:  Biomedicines       Date:  2021-07-31

Review 3.  Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.

Authors:  Claudia Maria Hattinger; Maria Pia Patrizio; Silvia Luppi; Massimo Serra
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

Review 4.  SNHG16: A Novel Long-Non Coding RNA in Human Cancers.

Authors:  Ming Yang; Wenbin Wei
Journal:  Onco Targets Ther       Date:  2019-12-31       Impact factor: 4.147

5.  Down-regulation of circular RNA hsa_circ_0007534 suppresses cell growth by regulating miR-219a-5p/SOX5 axis in osteosarcoma.

Authors:  Peng Zhang; Jun Li
Journal:  J Bone Oncol       Date:  2021-01-18       Impact factor: 4.072

6.  CircRNA hsa_circ_0005909 Promotes Cell Proliferation of Osteosarcoma Cells by Targeting miR-338-3p/HMGA1 Axis.

Authors:  Cailong Zhang; Na Na; Li Liu; Yingzhu Qiu
Journal:  Cancer Manag Res       Date:  2021-01-27       Impact factor: 3.989

7.  Hsa_circ_0032463 acts as the tumor promoter in osteosarcoma by regulating the miR‑330‑3p/PNN axis.

Authors:  Guanghua Qin; Xuejian Wu
Journal:  Int J Mol Med       Date:  2021-03-31       Impact factor: 4.101

8.  circPVT1 promotes osteosarcoma glycolysis and metastasis by sponging miR-423-5p to activate Wnt5a/Ror2 signaling.

Authors:  Jun Wan; Yupeng Liu; Feng Long; Jian Tian; Can Zhang
Journal:  Cancer Sci       Date:  2021-03-10       Impact factor: 6.716

9.  Hsa_circ_0008259 modulates miR-21-5p and PDCD4 expression to restrain osteosarcoma progression.

Authors:  Kai Guan; Shizhang Liu; Keke Duan; Xiaoxia Zhang; Huitong Liu; Bingqiang Xu; Xi Wang; Xin Jin
Journal:  Aging (Albany NY)       Date:  2021-12-14       Impact factor: 5.682

Review 10.  Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers.

Authors:  Guillaume Anthony Odri; Joëlle Tchicaya-Bouanga; Diane Ji Yun Yoon; Dominique Modrowski
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.